Teraflex capsules 500mg/400mg №60 №1

Name:
Teraflex caps 500mg/400mg in vial No. 60
Description:
Transparent hard gelatin capsules size No. 00, filled with white with slight shades, or light beige powder with crystalline particles. The main active ingredient Chondroitin sulfate + glucosamine Release form Capsules Pharmacological properties Glucosamine The pharmacodynamics of glucosamine hydrochloride has not been studied. Chondroitin sulfate Chondroitin sulfate is a high molecular weight mucopolysaccharide. It is the main component of proteoglycans, which, together with collagen fibers, make up the cartilage matrix. Indications for use Relief of symptoms (from mild to moderate pain), with a gradual development of the effect, with adequately diagnosed osteoarthritis of the knee, hip joints, osteochondrosis of the spine. Method of administration and doses Adults, including elderly patients The recommended dose is 1000-1200 mg of chondroitin sulfate and 1500 mg of glucosamine, i.e. 1 capsule 3 times a day. The recommended duration of treatment is at least 3-6 months. Children This medicinal product is not recommended for use in children and adolescents under 18 years of age due to lack of safety and efficacy data. Patients with impaired renal / hepatic function There are no data on the need for dose adjustment. The capsules may be taken before, during or after a meal. Patients who do not tolerate fasting medicines should take this medicine after a meal. Capsules should be swallowed with sufficient liquid. Application during pregnancy and lactation Due to the lack of sufficient clinical data on the use of glucosamine in pregnant women or excretion with breast milk, the use of the drug during pregnancy and breastfeeding is not recommended. Influence on the ability to drive a car or other mechanisms Special studies on the effect of the drug on the ability to drive vehicles and other mechanisms have not been conducted. If you experience headache, drowsiness, fatigue, dizziness or blurred vision, driving a car or operating machinery is not recommended. Precautions Before using the drug, you should consult your doctor to exclude the presence of joint diseases for which other methods of treatment are provided. Patients suffering from bronchial asthma should be informed about the possible worsening of the symptoms of the disease. In patients with impaired glucose tolerance, it is advisable to monitor blood glucose levels and, if necessary, determine the need for insulin before and periodically during treatment. Due to the lack of special studies in patients with renal or hepatic insufficiency, the use of the drug should be carried out under medical supervision. Very rarely, edema or fluid retention has been reported in patients with heart and/or renal insufficiency. The drug Teraflex contains 28 mg of sodium in one capsule. This should be taken into account by patients on a sodium-restricted diet. Interaction with other drugs Glucosamine Special studies on the interaction of glucosamine with other drugs have not been conducted. There are reports of an increased effect of coumarin anticoagulants, therefore, in patients who are simultaneously taking coumarin anticoagulants (for example, warfarin or acenocoumarol), more careful monitoring of coagulation parameters is necessary. It is acceptable to take steroidal or non-steroidal anti-inflammatory drugs at the same time as glucosamine. Chondroitin sulfate Interactions with other drugs are not described. Contraindications Children under 18 years of age, increased individual sensitivity to any of the components of the drug, allergic reactions to crustaceans, pregnancy, lactation. Composition 1 capsule contains active ingredients: glucosamine hydrochloride 500 mg, sodium chondroitin sulfate 400 mg; excipients: gelatin, stearic acid, magnesium stearate, manganese sulfate. Overdose Cases of overdose are not described. In case of an overdose, the drug should be discontinued. Treatment is symptomatic, aimed at restoring water and electrolyte balance. Side effects The following classification is used to assess the frequency of adverse reactions: very often (? 1/10), often (? 1/100, < 1/10), infrequently (? 1/1000, < 1/100), rarely (? 1/10,000, < 1/1,000), very rare (< 1/10,000), frequency unknown (cannot be estimated from the available data). From the gastrointestinal tract: often - dyspepsia, nausea, abdominal pain, diarrhea, constipation, bloating; rarely - vomiting. From the immune system: the frequency is unknown - allergic reactions, including flushing and skin rash, itching, urticaria, angioedema. From the skin and subcutaneous tissues: infrequently - erythema, itching, rash; frequency unknown - urticaria, angioedema. From the nervous system and sensory organs: often - headache, general weakness, drowsiness; frequency unknown - dizziness. On the part of the organ of vision: visual impairment. On the part of the respiratory system: the frequency is unknown - asthma, worsening of the course of asthma. From the side of the cardiovascular system: infrequently - hot flashes; frequency unknown - arrhythmias, including tachycardia. From the liver and biliary tract: the frequency is unknown - increased levels of "liver" enzymes in the blood and jaundice * * Jaundice and cases of increased levels of "liver" enzymes have been reported, but a causal relationship with glucosamine intake has not been established. Mental disorders: frequency unknown - insomnia. From the side of metabolism and nutrition: the frequency is unknown - inadequate glycemic control in diabetes. General disorders: often - fatigue; frequency unknown - edema, peripheral edema. On the part of laboratory and physiological parameters: the frequency is unknown - an increase in "liver" enzymes, blood glucose levels, an increase in blood pressure, fluctuations in the INR (international normalized ratio). Reporting adverse reactions In case of any adverse reactions, you should consult your doctor. This recommendation applies to any possible adverse reactions, including those not listed in the package insert. You can also report adverse reactions to the National Adverse Drug Reaction Information Database, including information on drug failures. By reporting adverse reactions, you help to get more information about the safety of the drug. Storage conditions At a temperature not exceeding 25 ° C, out of the reach of children. Buy Teraflex capsules 500mg/400mg №60 №1